Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06732895 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. | PHASE2 | RECRUITING | 24 | — | — | Dec 10, 2024 | Sep 1, 2027 | Apr 21, 2026 | 5 | Canada, Denmark +3 |
| NCT06079398 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia | PHASE2 | RECRUITING | 72 | — | — | Jan 23, 2024 | Dec 1, 2028 | Apr 8, 2026 | 18 | United States, Australia +13 |
cm per year
Incidence of treatment emergent adverse events (TEAEs)
Change from baseline to 52 weeks in length/height Z-score
| Arm | Type | Description |
|---|---|---|
| Navepegritide | EXPERIMENTAL | Once weekly double-blinded treatment with SC injection of 100 µg/kg of navepegritide for 52 weeks |
| Placebo for Navepegritide | PLACEBO_COMPARATOR | Once weekly double-blinded treatment with SC injection of 100 µg/kg of placebo for navepegritide for 52 weeks |
| Name | Type | Description |
|---|---|---|
| Navepegritide | DRUG | Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks |
| Placebo for navepegritide | DRUG | Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide |
Inclusion Criteria: * Written, signed informed consent and/or assent of the participant, participant parent(s) or legal guardian(s) of the participant, and as required by the institutional review board/human research ethics committee/independent ethics committee (IRB/HREC/IEC). For participants who...